focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
FRESH ANNOUNCEMENT 2 HOURS AGO.
Announcing the two new "mega labs", the government said they will use technology to speed up the process - for example through automation and robotics.
https://www.bbc.co.uk/news/uk-54953677
Sounds very similar to our collaboration with Beckman Coulter
John Rylands (ex CFO) holding has NOT changed. Due to the loan conversion & additional shares in circulation it has diluted him down a little. This RNS just confirms that.
Holding before conversion was 1,686,603 & is still 1,686,603 as per todays RNS!
Don't be fooled!
https://mobile.twitter.com/Moilgas/status/1313362862816071680
Both Moil and DIVOC have stated tests have begun or will begin by September 25th. In fact the DIVOC CEO himself tweeted this today wearing PPE. Give researchers credit where credit is due as they are doing it for us. I think David Budd is waiting to release 1 mega RNS and is testing everyone's patience now. Some great info out there on twitter...
https://mobile.twitter.com/kanavkahol/status/1308663932324728834
WHO is on very last stages. Given the fact info has already been requested on the dossier section and it was at that stage for 3 weeks it looks like it's at touching distance. Documents and status etc highlighted in detail on twitter which shows just a checklist is now outstanding. Either way it should be any day now as well as the several other outstanding news items.
https://mobile.twitter.com/Moilgas/status/1308505153079775233
I've seen a lot of good posts on twitter lately. Plenty of information with links and screenshots. Far better than just the chat format on here as people are backing up the claims with evidence. Might be worth having a look if you're looking for some snapshot information in bite size chunks. You need to search #gdr for all the Genedrive related posts to come up. Yes some are a bit rampy and repetitive but some are very informative.
Hi Joeline. Nothing to do with operation moonshot. In summary the university have given thier ABI7500 PCR machine to a army person so it can be better used for COVID-19 testing at a lab rather than lung conditions. They even took some PPE. I thonk you've totally misread the article.
Magsy18 and Safy
I've checked the twitter feed and it seems genuine enough. At the very least it's certainly informative with links to all the sources of information. I believe the chap has even put the screen shots of the calls on the closed group. Anyway each to thier own opinion. Some see it as ramping and some will see it as genuine. The bottom line is when the news arrives we will all know what's what so best to leave the guess work and criticism out and hold for the RNS if they are ever going to come. I recall you making some guesses yourself safy regarding timescales so if it's fine for you to do so then you should give others the opportunity to voice thier opinions too, you never know they might actually be right in comparison to what you had posted. I'm glad there's people out there doing the research for us all. Saves us time I suppose. Bottom line is, we should all invest, hold and sell based on our own research and strategy. If another poster is smart enough to make others invest thier well earned money then that's thier own fault for not being able to comprehend and understand the share themselves to make thier own decision.
The changes announced yesterday don't mean anything to GDR realistically as it is still up to the buyers of the kits (laboratories) to choose which kit they prefer to use. It's obvious that nobody will want to use a substandard kit as they would be providing thier customer doubtful results. The labs with the big contracts will only use the best tests simply because they are quality orientated and have a reputation to keep up. What's more important is the fact that the GDR kit is not only gold standard but it is also a lot less steps than the others too so it still will be very appealing. Reputable companies use reputable and accredited supplies especially given the fact that the tests cost upwards of $100 to the end user.
What this announcement also signals is there is clearly a shortage of tests in the USA market which are hampering the effort to get people tested. Easing of rules and regulations usually happens to get more supply into the market. Another advantage for us as we may end up with orders immediately from those less reputable labs that are not too fussed about thier prestige like Beckman or Quest are...
Let's see.
Check this post out on twitter! Looks like Beckman Coulter will be rolling out a fair few machines by September...
https://mobile.twitter.com/Moilgas/status/1294284185650298881
See link below. Looks like David is upto something in the UK too...
https://mobile.twitter.com/Moilgas/status/1294155286081667073
About time the penny dropped about our collaboration with Beckman. As my figures suggested, a tiny amount of 30,000 tests per day (achievable through just 10 machines) equates to nearly £90 million in revenue for Genedrive. Just shows how big this can end up being if we get a contract for several 10's of thousands of tests per day! The market will smell the roses eventually and this will constantly gap up until its worth at least £200 million. Thereafter, the size of the contract wins will dictate how far up it will go. Unless Beckman buy us out which to be honest at £200 or £300 million is loose change for them!
Plantpower. I agree.
They don't announce just anything to the market like a lot of companies. Looking at the recent announcements this year they tend to announce usual corporate stuff like Q1 and Q2 earnings or if they have had FDA approval or a major deal. A handful of quality and meaningful announcements. To announce the Genedrive collaboration means its something high up within the company and a venture they clearly deem as significant or important. Let see what they can do for us and for the USA
Beckman are Huge and are partners with big health care companies. They won't be validating this if they only have a couple of machines. They will have these machines all around the world so will sell it as a turnkey solution. All readily programmed. Not sure exactly how many they have but it will be a decent amount.
Grim, yes this is the news from the other day but what makes it more appealing is the fact that Beckman have also announced it. For example, when a small company partners with a large corporation you usually find the small company makes the announcement as its material to them but the large corporations tend not to as its not really that much of a game changer for them.
Prime example is oil and gas, many small cap players announce farm in or joint venture deals with Shell or BP etc via RNS but you dont see Shell making the announcements in the same fashion because what may be transformational for the small cap company may not be for Shell or BP. If the small company valuation is going from £5 million to £15 million it's transformational, if Shell go from £35 billion to £35.01 billion its nothing for them because it's all about scale and the impact it has on the overall business.
Safy
I agree. It will likely be trialled in 1 large lab to startboff but then get rolled out to those states where there is a shortage or real requirement for faster testing. Beckman are going to go big on this. They will likely have thier machines dotted all around the USA. They state one 8 hour shift can process 1000 tests. So thats 3000 tests per 24 hours. Even if this was to be implemented in 10 labs acrothe USA that equates to 30,000 rapid gold standard tests per 24 hour.
30,000 tests at £8 is £240,000 per 24 hours or £87.6 million per year.
That's based on a 24/7 roll-out on just 10 machines. The USA is testing hundreds of thousands of people per day so the scope and opportunity is gigantic. But as above even if they rolled it out across 10 labs and did 30k tests per 24 hours its transformational for Genedrive. Lets say they rolled it out to 20 labs and started hitting 60k tests per 24 hours, all of a sudden then numbers look ridiculous at around £170 million in revenue per annum. And that's if we sell them at £8, if you get the top end price at £10 add another 20% to the revenues... And you won't even be scratching the surface in the USA with 30k-60k tests. They should easily consume them.
Then there's the Indian scope, PHE scope, Africa scope etc etc.
Once this delivers, it will deliver big
Just a USA contract win of 30k tests a day should see us worth £250 - £300 million MCAP.
I reckon FDA approvals are incoming very quickly as they need to be in for Beckman to roll this out. They will have a significant degree of confidence that they are imminent hence making this announcement otherwise its a bit embarrassing if your announcing a collaboration but then have to go back track due to not getting approvals.
Just seen a post on twitter about a press release by Beckman Coulter. Seems positive that they are releasing this news to the US market too as normally you are only expected to announce something if its material to the company. I. E. Significant development that can affect the company materially.
Link for twitter post is below
https://mobile.twitter.com/Moilgas/status/1293834540880924673
Link for press release is :
https://www.beckman.com/news/beckman-coulter-collaborates-with-genedrive-plc-to-automate-high-throughput-sars-cov-2-pcr-testing
Fingers crossed.
With USA labs running at full capacity, the only way to increase testing now is:
1) Buy more PCR machines - Currently unavailable or long lead times.
2) Use faster tests - GDR has these - from 4 hours to 90 mins per 96 tests.
3) Automation - GDR/Beckman collaboration.
Other issues are shortage of chemical reagents. Luckily the GDR kit only requires the use of the swab sample and bead, not the several other reagents like other tests.
Also, this whole testing business is very lucrative. Quest charges $100 per each test. If they buy the GDR test for £10 or $13 USA, There is ample mark up and they can process more tests. Its a no brainer business decision.... I think big things willcome from the USA which David is rightly targeting.
One thing is for sure. If Beckman and GDR get this testing setup right it will most certainly get taken up across the world. It saves money, increases output and more importantly is accurate and error free. Automation is the way and with DIVOC also setting up a lab i wouldn't be surprised to see all this joining up to be a massive jigsaw puzzle using thousands of test kits every day across the globe. Let's hope David can pull it off, he's certainly got the right experience and right team with him to get this job done amazingly.